November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety of vericiguat, met the primary efficacy endpoint for reducing the risk of heart failure hospitalization and cardiovascular death in patients with worsening chronic heart failure with reduced ejection fraction (HFrEF). The new drug outperformed patients given a placebo in combination with available heart failure therapies. 

November 20, 2019 — Heart attack survivors may have an increased risk of developing cancer compared to people without cardiovascular disease, according to research presented at the American Heart Association’s Scientific Sessions 2019 — Nov. 16-18 in Philadelphia. The Association’s Scientific Sessions is an annual, premier global exchange of the latest advances in cardiovascular science for researchers and clinicians.

November 20, 2019 — Ultra-processed foods, which account for more than half of an average American’s daily calories, are linked to lower measures of cardiovascular health, according to preliminary research to be presented at the American Heart Association’s Scientific Sessions 2019 — Nov. 16-18 in Philadelphia. The Association’s Scientific Sessions is an annual premier global exchange of the latest advances in cardiovascular science for researchers and clinicians.

November 20, 2019 — Frequent cannabis (marijuana) use among young people was linked to an increased risk of stroke, and people diagnosed with cannabis use disorder were more likely to be hospitalized for heart rhythm disturbances (arrhythmias), according to two new preliminary studies to be presented at the American Heart Association’s Scientific Sessions 2019 — Nov. 16-18 in Philadelphia.

In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff

November 19, 2019 — After 12 years of collecting data, the results of the landmark ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) Trial showed patients with significant, but stable, coronary artery disease are better off with lifestyle changes and medications vs. stents or bypass surgery. However, patients who underwent revascularization procedures felt better and reported a better quality of life, the study found.

November 19, 2019 — Since Maquet/Datascope first recalled all of its  intra-aortic balloon pumps (IABP) due to reports of the batteries failing in November 2018, a year later the U.S. Food and Drug Administration said its has received more than 60 additional medical device reports related to this issue. These included two patient deaths and one serious patient injury.

The American Heart Association, AHA, 2019 meeting late breaking trials and key studies on cardiovascular science.

Here is a list of the key late-breaking clinical study presentations at the 2019 American Heart Association (AHA) annual meeting, Nov. 16-18, 2019, in Philadelphia.

(February 2020 update — the results of this trial led to the FDA clearnace of the Micra AV device in January 2020 - FDA Clears Medtronic Micra AV to Treat AV Block)

November 7, 2019 — The ClotTriever Outcomes (CLOUT) Registry is evaluating real-world patient outcomes following treatment of acute and non-acute lower extremity proximal deep vein thrombosis (DVT) with the ClotTriever system (Inari Medical), a mechanical thrombectomy system FDA 510(k) cleared for the nonsurgical removal of soft thrombi and emboli from peripheral blood vessels. The most recent data were presented at the 2019 Vascular Interventional Advances (VIVA) annual meeting.

November 7, 2019 — Ultrasoundplasty before angioplasty for below-the-knee lesions (BTK) lesions may improve clinical outcomes without the need for a drug-eluting device, acceding to data presented at the 2019 Vascular Interventional Advances (VIVA) annual meeting.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now